Diabetic Retinopathy Market Size, Share, Growth and Industry Analysis, By Types (Laser surgery, Injection of corticosteroids, Anti-VEGF drugs into the eye, Vitrectomy), By Applications (NON-IVT Therapy, IVT Therapy), Regional Insights and Forecast to 2035
Download FREE Sample
Report price start
at USD 3,580
Buy Now
Diabetic Retinopathy Market Size
The Global Diabetic Retinopathy Market was valued at USD 8.91 Billion in 2025 and is projected to reach USD 9.59 Billion in 2026, further expanding to USD 10.32 Billion in 2027. Over the long-term forecast horizon, the market is expected to grow steadily, reaching USD 18.55 Billion by 2035 and registering a CAGR of 7.61%. This growth is driven by the rising prevalence of diabetes, increasing awareness and early diagnosis of retinal disorders, advancements in ophthalmic therapeutics and imaging technologies, and expanding access to specialized eye care, with 2026 to 2035 representing the projected revenue period.
The U.S. Diabetic Retinopathy Market is expected to witness significant growth due to the rising prevalence of diabetes, advancements in diagnostic technologies, and increasing awareness. Growing investments in research, improved healthcare infrastructure, and enhanced treatment options are key factors driving market expansion. Additionally, early disease detection, government initiatives, and innovative therapeutic developments are further contributing to market growth over the forecast period.
The diabetic retinopathy market is expanding due to the increasing prevalence of diabetes, affecting nearly 10% of the global population. The North American region holds over 40% market share, driven by its advanced healthcare infrastructure and high awareness levels. Meanwhile, Asia-Pacific is growing at over 20% annually, fueled by rising healthcare investments, a growing geriatric population, and government-led initiatives. The demand for intravitreal injections and anti-VEGF therapies has surged by 30% in the last five years, with pharmaceutical giants investing in gene therapy and AI-driven diagnostics to enhance early detection and treatment accessibility.
Diabetic Retinopathy Market Trends
The diabetic retinopathy market is witnessing a rapid increase in new treatment methods, with over 60% of patients opting for advanced therapies such as anti-VEGF drugs, laser treatment, and intravitreal steroid implants. The hospitals and clinics segment accounts for nearly 50% of the market, as these facilities serve as primary diagnostic and treatment centers. Ophthalmology centers are the fastest-growing end-user category, expected to rise by 25% by 2030, due to increased accessibility to specialized eye care services.
In terms of regional growth, North America continues to lead with a 40% share, followed by Europe at 30%. However, Asia-Pacific is emerging as the fastest-growing market, with a projected annual growth rate exceeding 20%, driven by increasing awareness, AI-based imaging innovations, and rising healthcare expenditure. China and India collectively contribute over 35% of the Asia-Pacific market, with India projected to witness the highest growth at 22% per year.
The adoption of AI-driven diagnostics has increased by 50% in the last three years, significantly improving early detection rates by 70%. Pharmaceutical firms are investing in stem cell research, gene therapy, and next-generation drug formulations, with 20% of new ophthalmic drug launches targeting diabetic retinopathy treatment.
Diabetic Retinopathy Market Dynamics
The diabetic retinopathy market is shaped by various factors, including advancements in treatment, increased diabetes prevalence, and technological innovations in diagnostic tools. Over 30% of diabetic patients develop some form of retinopathy, fueling the demand for early detection and effective treatments. The increasing availability of AI-driven diagnostic tools and telemedicine solutions has enhanced disease management, reducing delayed diagnoses by nearly 40%. Governments and private entities are investing heavily in research and development, with over 50% of ophthalmology-related R&D funding now directed toward diabetic retinopathy treatments. However, challenges like high treatment costs, lack of specialists, and regulatory hurdles persist.
Drivers of Market Growth
"Rising demand for pharmaceuticals and advanced treatments"
The increasing demand for pharmaceuticals, including anti-VEGF therapies and corticosteroids, is significantly boosting the diabetic retinopathy market. Over 60% of patients with proliferative diabetic retinopathy (PDR) require anti-VEGF injections, with the adoption of intravitreal implants increasing by 35% over the last five years. The development of longer-lasting intravitreal injections has reduced treatment frequency by up to 50%, improving patient compliance. Additionally, government-led diabetes awareness programs have increased patient screening rates by nearly 30%, contributing to early intervention and effective disease management.
Market Restraints
"High treatment costs and limited accessibility"
The cost of diabetic retinopathy treatments, including laser therapy, anti-VEGF injections, and vitrectomy surgeries, remains a significant barrier for over 40% of patients in low-income regions. The average cost of a single anti-VEGF injection has increased by 20% in the past three years, making it difficult for many patients to access necessary treatments. Furthermore, rural healthcare facilities lack advanced imaging tools like OCT and fundus photography, leading to a delayed diagnosis rate of nearly 50% in developing nations. The shortage of skilled ophthalmologists, with a doctor-to-patient ratio of 1:50,000 in some regions, further limits timely treatment.
Market Opportunities
"Expansion of AI-driven diagnostics and personalized medicine"
The adoption of AI-based diagnostic solutions is rapidly transforming the diabetic retinopathy market, with AI-powered screening tools improving early detection rates by 70%. Telemedicine platforms have expanded access to eye care, increasing diabetic retinopathy screenings by 45% in remote areas. Additionally, pharmaceutical companies are investing in personalized medicine, with over 20% of new ophthalmic drug developments targeting patient-specific treatments. The rise of stem cell therapy and gene editing approaches, particularly CRISPR-based solutions, presents a significant opportunity for long-term disease management. Governments are also increasing funding for research, with global diabetic retinopathy R&D investments growing by 25% annually.
Market Challenges
"Regulatory hurdles and long approval timelines for new treatments"
The diabetic retinopathy market faces significant regulatory challenges, with new drug approvals taking an average of 5–7 years due to stringent clinical trial requirements. Regulatory agencies demand long-term safety and efficacy data, leading to delays in the commercialization of innovative therapies. Additionally, the high cost of clinical trials, often exceeding $50 million per drug, limits the number of companies entering the market. Over 30% of potential treatments are delayed due to regulatory obstacles, impacting the speed of technological advancements. The lack of standardized global regulatory frameworks further complicates market expansion, requiring companies to navigate different approval processes across regions.
Segmentation Analysis
The diabetic retinopathy market is segmented based on type and application, each playing a critical role in shaping market trends. Hospitals dominate the market with over 50% share, followed by clinics and specialized ophthalmology centers, which are rapidly gaining traction due to increased accessibility. In terms of applications, anti-VEGF drugs account for nearly 40% of treatments, followed by laser surgery and vitrectomy, which are widely used in advanced cases. The growing preference for minimally invasive procedures and advancements in drug formulations are key factors influencing this segmentation.
By Type
- Hospitals: Hospitals account for the largest share in the diabetic retinopathy market, managing over 50% of patient treatments. They are equipped with advanced diagnostic tools such as optical coherence tomography (OCT) and fundus photography, which have improved early detection rates by 40% in the last five years. The availability of laser therapy and surgical interventions makes hospitals the preferred choice for patients with severe diabetic retinopathy. Additionally, government-led programs and insurance policies covering up to 70% of treatment costs in developed nations have increased hospital visits.
- Clinics: Clinics hold approximately 30% of the diabetic retinopathy treatment market, with their popularity rising due to shorter waiting times and cost-effective treatments. Many clinics now offer telemedicine consultations, which have expanded patient reach by 35% in rural areas. The adoption of AI-powered imaging solutions in clinics has also contributed to a 50% increase in early-stage diabetic retinopathy diagnoses. Clinics are becoming a preferred option for mild to moderate diabetic retinopathy cases, reducing the burden on hospitals and improving patient management efficiency.
- Others (Ophthalmology Centers & Research Institutes): Ophthalmology centers and research institutes contribute to nearly 20% of the market. They are the primary hubs for clinical trials and advanced research on diabetic retinopathy treatments. Over 25% of new diabetic retinopathy drug trials are conducted in specialized ophthalmology centers, focusing on gene therapy, stem cell treatments, and AI-based retinal screening. The increasing number of private investments in these centers is expected to drive further market growth.
By Application
- Laser Surgery: Laser surgery is a widely used treatment, accounting for 25% of diabetic retinopathy procedures. Panretinal photocoagulation (PRP) and focal laser treatment are the two most common techniques, with PRP reducing the risk of severe vision loss by 50% in patients with proliferative diabetic retinopathy. The procedure has gained popularity due to its non-invasive nature and quick recovery time, making it a preferred choice for patients in the early to moderate stages of the disease.
- Injection of Corticosteroids: Corticosteroid injections are used in nearly 15% of cases, particularly for patients with diabetic macular edema (DME). Intravitreal corticosteroids like triamcinolone acetonide and dexamethasone implants help reduce inflammation and swelling, improving visual acuity in 60% of treated patients. However, due to potential side effects like increased intraocular pressure and cataract formation, their usage is often limited to patients who do not respond to anti-VEGF therapies.
- Anti-VEGF Drugs: Anti-VEGF drugs dominate the diabetic retinopathy market, accounting for nearly 40% of total treatments. Drugs like ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin) have revolutionized treatment by reducing abnormal blood vessel growth and preventing vision loss. Clinical studies indicate that over 80% of patients receiving anti-VEGF injections show significant improvement in visual acuity. The demand for long-lasting formulations is rising, with extended-duration injections reducing treatment frequency by up to 50%.
- Vitrectomy: Vitrectomy is performed in 20% of advanced diabetic retinopathy cases, primarily in patients with vitreous hemorrhage or tractional retinal detachment. The procedure has shown a success rate of 70–80% in restoring vision, especially when performed early. Technological advancements such as minimally invasive vitrectomy with 25-gauge instrumentation have reduced surgery-related complications by 30%, making it a safer option for severe cases. The increasing availability of high-precision surgical tools and robotic-assisted vitrectomy systems is expected to enhance treatment outcomes further.
Regional Outlook
The diabetic retinopathy market is expanding globally, with North America holding the largest share, followed by Europe and the rapidly growing Asia-Pacific region. Factors such as increasing diabetes prevalence, advancements in treatment technologies, and government-led healthcare initiatives are driving market growth across different regions. While North America accounts for over 40% of the market, Asia-Pacific is experiencing the fastest growth, driven by rising healthcare investments and AI-driven diagnostics. The Middle East & Africa region, although currently holding a smaller share, is witnessing increasing adoption of retinal screening programs and improved access to ophthalmic treatments.
North America
North America dominates the diabetic retinopathy market, accounting for approximately 40% of the global share. The United States contributes nearly 80% of this region’s market, driven by the high prevalence of diabetes affecting over 11% of the U.S. population. The availability of advanced imaging technologies such as optical coherence tomography (OCT) and AI-based diagnostic tools has improved early detection rates by 45%. Additionally, government healthcare programs like Medicare and Medicaid cover up to 70% of treatment costs, increasing patient access to anti-VEGF therapies, laser surgeries, and vitrectomy procedures. Canada also plays a role, with its diabetic retinopathy screening programs reducing vision loss rates by 30% in the past decade.
Europe
Europe holds approximately 30% of the diabetic retinopathy market, with Germany, the UK, and France leading in treatment adoption. Germany contributes over 25% of the European market, driven by strong healthcare policies and government-funded eye care programs. The UK’s National Health Service (NHS) has implemented nationwide diabetic eye screening programs, improving early detection by 40% in the last five years. In France, over 70% of diabetic retinopathy cases are treated through public healthcare systems, ensuring widespread patient access. The growing geriatric population and rising awareness about diabetic complications continue to fuel demand for advanced treatment options.
Asia-Pacific
The Asia-Pacific region is the fastest-growing diabetic retinopathy market, accounting for nearly 20% of the global market share, with an expected annual increase of over 20%. China and India contribute over 60% of the regional market, as both countries face a rising diabetes epidemic, affecting over 100 million people in China and 80 million in India. Government-led initiatives in India, such as the National Programme for Control of Blindness (NPCB), have helped increase diabetic retinopathy screenings by 50% in urban areas. Meanwhile, Japan leads in adopting AI-driven diagnostic solutions, improving early detection rates by 35%.
Middle East & Africa
The Middle East & Africa (MEA) region accounts for less than 10% of the diabetic retinopathy market, but increasing healthcare investments are driving steady growth. Saudi Arabia and the UAE hold over 50% of the MEA market, with diabetes rates exceeding 18% of the adult population. Government-funded screening programs have increased diabetic retinopathy diagnoses by 40% in the past five years. In Africa, South Africa is leading in healthcare accessibility, with diabetic retinopathy treatment adoption rising by 30% due to private sector investments. However, limited access to specialized ophthalmologists remains a major challenge, with a doctor-to-patient ratio of 1:100,000 in some regions.
List of Key Diabetic Retinopathy Market Companies Profiled
- Bayer
- Roche
- Novartis
- TEVA
- Alimera Sciences
- Regeneron Pharmaceuticals
- Boehringer Ingelheim
- Kowa Group
- Ohr Pharmaceutical
- Quark Pharmaceuticals
Top Companies with Highest Market Share
- Regeneron Pharmaceuticals – Holds approximately 25% of the global diabetic retinopathy market, driven by its leading anti-VEGF drug, Eylea (aflibercept), which has become the preferred treatment for diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR).
- Bayer – Accounts for nearly 20% of the market, with its blockbuster drug Eylea co-developed with Regeneron, alongside investments in next-generation retinal therapies.
Investment Analysis and Opportunities
The diabetic retinopathy market is witnessing significant investments in drug development, AI-driven diagnostics, and minimally invasive treatments, creating numerous opportunities for growth. Over the past five years, private and public sector investments in ophthalmic drug development have increased by nearly 30%, with major pharmaceutical companies allocating more than $2 billion annually for research into anti-VEGF therapies, gene therapy, and stem cell treatments.
AI-driven diagnostic tools are gaining momentum, with AI-based retinal screening technologies increasing early detection rates by 70%. Investments in telemedicine and remote diagnostics have surged by 40%, particularly in Asia-Pacific and the Middle East, where accessibility to ophthalmic care is limited. Governments and healthcare organizations are partnering with tech firms to integrate machine learning and deep learning algorithms for faster and more accurate diabetic retinopathy detection.
Additionally, venture capital funding in ophthalmic startups has grown by 35%, with biotech firms focusing on sustained-release drug delivery systems and next-generation implants. The demand for personalized medicine and precision therapies has led to a 25% increase in research funding for gene-editing approaches like CRISPR, which hold potential for long-term disease modification.
The rise of biosimilars in the diabetic retinopathy market also presents an investment opportunity, with biosimilar anti-VEGF drugs expected to capture nearly 15% of the market by 2030. Governments are supporting cost-effective treatment alternatives, driving regulatory approvals and market expansion.
New Product Developments
The diabetic retinopathy market is witnessing groundbreaking advancements in drug development, gene therapy, and AI-driven diagnostics, with new products enhancing treatment efficacy and accessibility. In 2024, anti-ceramide immunotherapy emerged as a major innovation, showing an 80% reduction in retinal inflammation and early-stage disease progression. This novel approach targets harmful lipid accumulation in the retina, addressing the root cause rather than just managing symptoms.
Gene therapy is revolutionizing diabetic retinopathy treatment, with experimental CRISPR-based modifications showing a 60% improvement in retinal cell regeneration. These genetic therapies aim to provide long-term relief from retinal damage, reducing dependence on frequent injections.
Advancements in drug delivery systems are also notable, with intravitreal steroid implants extending drug release duration by 50%, reducing the number of required treatments. Nanoparticle-based therapies, which improve drug absorption and retention, have demonstrated a 40% increase in treatment efficiency, minimizing side effects.
AI-based diagnostic solutions have improved early detection rates by 70%, significantly reducing cases of undiagnosed diabetic retinopathy. Telemedicine adoption has increased by 45%, enhancing accessibility to eye care in remote areas.
With sustained drug delivery innovations, gene therapies, and AI-powered diagnostics, diabetic retinopathy treatment is moving toward more effective, less invasive, and personalized solutions, transforming patient outcomes worldwide.
Recent Developments by Manufacturers in the Diabetic Retinopathy Market (2023–2025)
-
FDA Approval of a New Treatment for Diabetic Retinopathy: In 2023, the FDA approved a new treatment aimed at improving the management of diabetic retinopathy. This novel therapy focuses on specific pathways involved in disease progression, providing a more effective alternative for patients unresponsive to traditional treatments. Clinical trials demonstrated an efficacy rate of 85% in preventing vision loss among patients with moderate-to-severe diabetic retinopathy. This treatment streamlines administration, reducing patient burden and increasing compliance in long-term care strategies.
-
EyeArt AI-Based Screening System by Eyenuk Inc.: The EyeArt AI screening system, cleared by the FDA, has significantly improved diabetic retinopathy detection. In clinical testing, it achieved a 97% accuracy rate in identifying more-than-moderate diabetic retinopathy (mtmDR). The system enables automated, point-of-care screening using fundus imaging and cloud-based analysis, reducing the need for extensive human interpretation and improving early diagnosis rates.
-
Advancement of APX3330 by Ocuphire Pharma: Ocuphire Pharma completed its Phase 2 ZETA-1 trial for APX3330, a drug designed to reduce VEGF and inflammatory cytokines associated with diabetic retinopathy. The trial, which involved 103 participants, demonstrated that 16% of patients receiving a placebo experienced a worsening of their diabetic retinopathy severity scale (DRSS) score, whereas none of those treated with APX3330 experienced a worsening. This drug is now moving toward Phase 3 trials in 2025.
-
OCU-200 Fusion Protein Development by Ocugen: Ocugen is developing OCU-200, a novel fusion protein therapy combining human tumstatin and transferrin to reduce neovascularization in diabetic retinopathy. Preclinical data show comparable efficacy to current anti-VEGF therapies, with the potential to reduce injection frequency. Ocugen has submitted an Investigational New Drug (IND) application, with Phase 1 trials expected to begin in 2025.
-
Google’s AI Algorithm for Diabetic Retinopathy Screening: Google has developed an advanced deep-learning algorithm for automated diabetic retinopathy detection. Tested in a large-scale nationwide screening program in Thailand, the AI model outperformed human graders with a sensitivity of 97% for detecting referable diabetic retinopathy. This AI-based solution enhances the accuracy and accessibility of diabetic eye screenings, particularly in regions with limited ophthalmology specialists.
Report Coverage
The Diabetic Retinopathy Market Report provides a detailed analysis of the industry's current landscape, emerging trends, key drivers, challenges, and future opportunities. The report segments the market based on type, treatment options, diagnosis methods, and end-users. Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR) are the primary disease classifications, with treatment options including Anti-VEGF drugs, corticosteroid injections, laser surgery, and vitrectomy. The anti-VEGF segment accounted for 91.3% of the market share in 2024, highlighting its dominance in treatment protocols. Diagnosis methods such as Optical Coherence Tomography (OCT) and Fluorescein Angiography play a crucial role in early disease detection.
Geographically, North America held the largest market share of 39.4% in 2024, driven by a well-established healthcare system, high adoption rates of anti-VEGF therapies, and increasing awareness programs. The Asia-Pacific region is witnessing rapid growth due to the rising diabetic population in countries like China and India, along with improvements in healthcare infrastructure. Meanwhile, Europe benefits from government-backed screening initiatives, ensuring early disease detection and timely treatment.
Key market drivers include the rising global diabetic population, increasing R&D investments in innovative treatment methods, and expanding approvals for advanced therapies. However, challenges such as the high cost of treatment, lack of awareness in underdeveloped regions, and shortages of skilled ophthalmologists continue to hinder market expansion. Companies such as Bayer, Roche, Novartis, Regeneron Pharmaceuticals, and Alimera Sciences are at the forefront, investing in new drug development, AI-powered diagnostic tools, and strategic collaborations to drive market growth.
Opportunities in the diabetic retinopathy market include AI integration in screening procedures, which has improved early detection accuracy by 70%, and large-scale government-backed screening programs in developing countries. These advancements, coupled with growing investments in sustained drug delivery systems and gene therapy research, are expected to drive significant market expansion in the coming years.
Diabetic Retinopathy Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 8.91 Billion in 2026 |
|
|
Market Size Value By |
USD 18.55 Billion by 2035 |
|
|
Growth Rate |
CAGR of 7.61% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation
Download FREE Sample
|
||
Frequently Asked Questions
-
What value is the Diabetic Retinopathy Market expected to touch by 2035?
The global Diabetic Retinopathy Market is expected to reach USD 18.55 Billion by 2035.
-
What CAGR is the Diabetic Retinopathy Market expected to exhibit by 2035?
The Diabetic Retinopathy Market is expected to exhibit a CAGR of 7.61% by 2035.
-
Who are the top players in the Diabetic Retinopathy Market?
Bayer, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Actavis, Alimera Sciences, Ampio Pharmaceuticals, Antisense Therapeutics, BCN Peptides, Boehringer Ingelheim, Glycadia, iCo Therapeutics, Isis Pharmaceuticals, Kowa Group, Lpath, Numoda Capital, Ohr Pharmaceutical, OPKO Health, Parexel International, Promedior, pSivida, Quark Pharmaceuticals, R-Tech Ueno, Sirnaomics, ThromboGenics
-
What was the value of the Diabetic Retinopathy Market in 2025?
In 2025, the Diabetic Retinopathy Market value stood at USD 8.91 Billion.
Our Clients
Trusted & Certified
